U.S. Senate · April 23, 2026
Roll call 103 · 119th Congress, session 2
S.Amdt. 5336 — To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal…
A vote on a proposed change to the bill A vote on one change, not on the bill. A bill can collect dozens of these, and losing one does not stop it.
Failed
48 yes 50 no
The Senate said no · recorded as “Amendment Rejected”
Needed a simple majority — more than half of those voting.
What was being voted on
119-SAMDT-5336 — To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.
SA 5336, submitted by Mr. Wyden, aims to add a section to title III of S. Con. Res. 33. The purpose is to create a deficit-neutral reserve fund regarding the duties of the Comptroller General of the United States. This amendment would allow the Chairman of the Senate Committee on the Budget to adjust budgetary levels and the pay-as-you-go ledger for legislation reported by the Senate Committee on Homeland Security and Governmental Affairs.
